Cormorant Asset Management Fully Exits Arcellx Stake
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Source: NASDAQ.COM
- Complete Liquidation: Cormorant Asset Management sold 775,000 shares of Arcellx in Q4, fully liquidating its position, resulting in a $63.63 million decrease in the fund's quarter-end value, indicating a significant shift in its investment strategy.
- Change in Investment Proportion: Previously, Arcellx accounted for 4.4% of the fund's AUM, and this exit reflects a waning confidence in the company, which may influence future investment decisions by Cormorant.
- Market Reaction: Despite Cormorant's exit leading to losses, Arcellx's stock has surged 80% this year, primarily driven by interest from larger pharmaceutical companies in its next-generation CAR-T cell therapies, highlighting strong market interest.
- Acquisition Agreement Impact: The acquisition agreement with Gilead Sciences, valuing Arcellx at approximately $7.8 billion and offering shareholders $115 per share in cash, could accelerate the development and commercialization of its therapies, although Cormorant's timing of exit missed this potential upside.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
